Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521971 | 0.87 | DGAT1 (0.39) | DGAT1HPGDSKCNH2 | |
| SCHEMBL15745367 | 0.84 | PIM1 (0.48) | DGAT1PIM1HPGDSKCNH2RXRA | |
| SCHEMBL18661369 | 0.81 | DGAT1 (0.42) | DGAT1PIM1HPGDSFLT1KDR | |
| SCHEMBL15733091 | 0.80 | DGAT1 (0.53) | DGAT1KCNH2KDR | |
| SCHEMBL15522136 | 0.79 | DGAT1 (0.41) | DGAT1DHFRKCNH2KDR | |
| SCHEMBL15745364 | 0.78 | KDM4E (0.38) | DGAT1 | |
| SCHEMBL15742157 | 0.76 | DGAT1 (0.42) | DGAT1HPGDSKCNH2KDR | |
| SCHEMBL15733050 | 0.75 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL14062292 | 0.74 | PTK2 (0.36) | DGAT1 | |
| SCHEMBL21077669 | 0.74 | DGAT1 (0.41) | DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492474-B1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3492474-B1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3492474-A1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492474-A1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-9796729-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796729-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9738658-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738658-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2922551-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081994-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885PIM1 3739/4885HPGDS 453/4885 |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885PIM1 1681/4885HPGDS 1062/4885 |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885PIM1 3739/4885HPGDS 453/4885 |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885PIM1 3739/4885HPGDS 453/4885 |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | DGAT1 1/4885PIM1 1484/4885HPGDS 1204/4885 |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885PIM1 1681/4885HPGDS 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.